{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T15:29:48Z","timestamp":1781796588596,"version":"3.54.5"},"reference-count":0,"publisher":"The Medical Letter, Inc.","issue":"1684","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Med Lett Drugs Ther"],"abstract":"<jats:p>The alkylating agent melphalan (Hepzato \u2013 Delcath) has been approved by the FDA for treatment of uveal melanoma in adults with unresectable hepatic metastases that affects &lt;50% of the liver and no extrahepatic disease, or extrahepatic disease limited to the bone, lymph nodes, subcutaneous tissues, or lung that is amenable to resection or radiation.<\/jats:p>","DOI":"10.58347\/tml.2023.1684d","type":"journal-article","created":{"date-parts":[[2023,9,6]],"date-time":"2023-09-06T15:45:54Z","timestamp":1694015154000},"page":"e148-e148","source":"Crossref","is-referenced-by-count":3,"title":["In Brief: Melphalan (Hepzato) for Uveal Melanoma"],"prefix":"10.58347","volume":"65","author":[{"name":"Editors from The Medical Letter","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"37151","published-online":{"date-parts":[[2023,9,4]]},"container-title":["The Medical Letter on Drugs and Therapeutics"],"original-title":[],"deposited":{"date-parts":[[2023,9,6]],"date-time":"2023-09-06T15:45:54Z","timestamp":1694015154000},"score":1,"resource":{"primary":{"URL":"https:\/\/secure.medicalletter.org\/TML-article-1684d"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,4]]},"references-count":0,"journal-issue":{"issue":"1684","published-online":{"date-parts":[[2023,9,4]]}},"URL":"https:\/\/doi.org\/10.58347\/tml.2023.1684d","relation":{},"ISSN":["1523-2859"],"issn-type":[{"value":"1523-2859","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9,4]]}}}